EANS-News: Semperit AG Holding / Semperit achieved historic records in revenue and earnings in the crisis environment of 2020

Corporate news transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.

Annual Reports/Financial Figures/Balance Sheet/Earnings/Annual Result

Vienna/Austria -

  • Significant increase in consolidated revenue by 10.4% to EUR 927.6 million
  • Strong increase in revenue in the Medical Sector (+53.1%), decline in the Industrial Sector (-12.6%)
  • EBITDA more than tripled to EUR 208.6 million, EBITDA margin improved from 8.1% to 22.5%
  • Turnaround in EBIT: strong increase to EUR 237.8 million (previous year: EUR -16.5 million)
  • Free cash flow almost tripled to EUR 176.2 million and significantly strengthened liquidity and financial power
  • Dividend proposal of EUR 1.50 per share with a dividend yield of 6.2% by the end of 2020

18 March 2021 - In the context of a global economic slowdown, which was further aggravated by the outbreak of the corona pandemic, the publicly listed Semperit Group achieved the best result in its recent corporate history: "The pandemic-related special economic situation in the business for medical protective gloves undoubtedly gave us a boost and led to an exceptionally high return on assets. However, we have also significantly increased our base profitability aside from this specific effect," says Martin Füllenbach, CEO of Semperit AG Holding. "Historic record figures for revenue, EBITDA, EBIT and free cash flow prove not only that our restructuring and transformation measures have broadly taken effect, but also that the Group is now profitably positioned for the future. The start of our cost-cutting programme, which is already having a clearly positive effect, is accompanied by a comprehensive strategy project to shape the best possible starting point for the years ahead."

Contrasting developments in the Industrial and Medical Sectors

The revenue increase of 10.4% to EUR 927.6 million achieved in 2020 marks the best year in the history of the Semperit Group since the turn of the millennium. The 53.1% increase in revenue in the Medical Sector was largely triggered by exceptionally high demand in combination with a significant price increase for medical protective gloves as a result of the corona pandemic. However, this success was only possible due to the lengthy and intensive restructuring efforts of the past years, which enabled higher capacity utilisation with increased production volumes.

Although the corona pandemic further intensified the economic downturn that had already begun in 2019 and left its mark on the revenue development of the Industrial Sector, it recorded a moderate decline in revenue of 12.6% compared to other industries.

As a result of the rapid increase in revenue, Group EBITDA more than tripled from EUR 67.8 million in 2019 to EUR 208.6 million in 2020. In addition to the positive effects of the pandemic on the Medical Sector, the Industrial segments also proved to be very resilient in a very challenging environment thanks to successful restructuring and are in total only EUR 10.8 million below the previous year's result. The EBITDA margin of the Semperit Group thus more than doubled from 8.1% to 22.5%.

EBIT improved to EUR 237.8 million in 2020, compared to EUR -16.5 million in the previous year. The EBIT margin adjusted for gains from the reversal of the impairments and impairment losses reached 18.5%, more than five times the value in 2019.

In 2020, cash-relevant investments in tangible and intangible assets at EUR 26.4 million were below the previous year's level of EUR 31.9 million. The main focus was on capacity-maintaining investments; expansion investments were only made to a minor extent.

Dividend proposal and outlook 2021

The dividend policy of the Semperit Group basically aims at distributing around 50% of earnings after tax - provided that business development continues successfully, and no extraordinary circumstances arise. However, the group is currently undergoing a profound transformation into an industrial rubber specialist, albeit somewhat delayed by the pandemic. For this purpose, one or more comprehensive company acquisitions are also intended, for which the corresponding financial strength is required. It is therefore possible to deviate from a pay-out ratio at around 50% for the duration of this strategic transformation in order to be financially strong for potential company acquisitions. This strategic realignment is in the best interest of all shareholders.

In the face of the successful business year and under these premises, the Executive Board will propose a dividend of EUR 1.50 per share at the Annual General Meeting, after no dividend was distributed in the past three years. A total of EUR 30.8 million will be distributed for the 2020 financial year. At a share price of EUR 24.30 at the end of 2020, this results in a dividend yield of 6.2%. The dividend proposal is not only intended to honour the loyalty of long-term investors, but also to send a positive signal regarding the business performance to be expected in the future at the same time. Simultaneously, the Executive Board will timely repay in full the outstanding hybrid capital of EUR 30.0 million provided by the core shareholder B & C Holding Österreich GmbH.

The Executive Board expects a perceptible recovery of the markets in the Industrial Sector for 2021. At the same time, there is currently no reason to implement the separation from the medical business, which has been decided and is still planned: the temporary goal is to benefit from the attractive profit contributions from the medical business as long and as comprehensively as possible. The Executive Board is very confident that the pandemic-related positive effects in the medical business will continue in 2021.

At Group level, the management's focus is on the consistent continuation of the cost-reduction programme initiated in 2020 in order to release further earnings potentials. This will be supported by systematic and continuous improvement in all areas of the company, which should further promote the competitiveness and sustainability of the Semperit Group.

Based on current figures, the Executive Board of Semperit AG Holding expects the Group's EBITDA for the full year 2021 to be around EUR 395.0 million and thus significantly above the EBITDA for the 2020 financial year. This earnings forecast depends in particular on the timely availability of necessary raw materials and their price development, the sales prices for medical protective gloves during the course of the year, and sufficient container availability for the delivery of Semperit Group's products


______________________________________________________________________________ |Key performance | 2020| Change| 2019| |figures,_in_EUR_m_|___________________|___________________|___________________| |Revenue___________|______________927.6|______________10.4%|______________840.6| |EBITDA_adjusted___|______________208.6|______________>100%|_______________63.8| |EBITDA margin | 22.5%| +14.9PP| 7.6%| |adjusted__________|___________________|___________________|___________________| |EBITDA____________|______________208.6|______________>100%|_______________67.8| |EBITDA_margin_____|______________22.5%|____________+14.4PP|_______________8.1%| |EBIT_adjusted_____|______________171.4|______________>100%|_______________28.2| |EBIT margin | 18.5%| +15.1PP| 3.4%| |adjusted__________|___________________|___________________|___________________| |EBIT______________|______________237.8|______________>100%|______________-16.5| |EBIT_margin_______|______________25.6%|____________+27.6PP|______________-2.0%| |Earnings after tax| 121.9| >100%| -0.2| |adjusted__________|___________________|___________________|___________________| |Earnings_after_tax|______________194.6|______________>100%|______________-44.9| |Earnings per share| 9.06| >100%| -2.50| |(EPS),_in_EU______|___________________|___________________|___________________| |Gross_cashflow____|______________193.7|______________>100%|_______________46.7| |Free_cashflow_____|______________176.2|______________>100%|_______________60.8| |__________________|___________________|___________________|___________________| |Balance sheet key | | | | |figures, in EUR m | 2020| Change| 2019| |(at balance sheet | | | | |date)_____________|___________________|___________________|___________________| |Balance sheet | 764.4| 8.9%| 701.8| |total_____________|___________________|___________________|___________________| |Equity____________|______________332.3|______________21.5%|______________273.4| |Net_debt__________|_______________22.1|_____________-69.9%|_______________73.5| |Net debt / EBITDA | 0.1| -90.2%| 1.1| |ratio_____________|___________________|___________________|___________________| |Additions to | | | | |tangible and | 28.5| -9.2%| 31.4| |intangible_assets_|___________________|___________________|___________________| |__________________|___________________|___________________|___________________| |ESG_______________|_______________2020|_____________Change|_______________2019| |Employees (at | | | | |balance sheet | 6,943| 0.6%| 6,902| |date)_____________|___________________|___________________|___________________| |__________________|___________________|___________________|___________________| |Sector and segment| | | | |key figures, in | 2020| Change| 2019| |EUR_m_____________|___________________|___________________|___________________| |Industrial_Sector:|___________________|___________________|___________________| |Sales_____________|______________478.4|_____________-12.6%|______________547.2| |EBITDA____________|_______________76.6|_____________-12.4%|_______________87.5| |EBIT______________|_______________32.4|_____________-46.7%|_______________60.9| |___Semperflex:____|___________________|___________________|___________________| |___Sales__________|______________189.9|_____________-14.7%|______________222.7| |___EBITDA_________|_______________41.9|_____________-12.6%|_______________47.9| |___EBIT___________|_______________30.9|_____________-14.1%|_______________36.0| |___Sempertrans:___|___________________|___________________|___________________| |___Sales__________|______________113.1|_____________-15.6%|______________134.0| |___EBITDA_________|________________8.7|_____________-35.6%|_______________13.5| |___EBIT___________|______________-14.9|______________>100%|________________8.9| |___Semperform:____|___________________|___________________|___________________| |___Sales__________|_______________81.8|_____________-10.3%|_______________91.1| |___EBITDA_________|_______________15.0|______________-3.9%|_______________15.6| |___EBIT___________|_______________11.3|______________-5.8%|_______________12.0| |___Semperseal:____|___________________|___________________|___________________| |___Sales__________|_______________93.6|______________-5.9%|_______________99.5| |___EBITDA_________|_______________11.0|_______________5.6%|_______________10.4| |___EBIT___________|________________5.1|______________28.4%|________________4.0| |Medical Sector | | | | |(Sempermed):______|___________________|___________________|___________________| |Sales_____________|______________449.2|______________53.1%|______________293.3| |EBITDA____________|______________150.4|______________>100%|________________5.5| |EBIT______________|______________224.9|______________>100%|______________-50.2|

For further details please see the Semperit Group's Annual Report 2020.

end of announcement euro adhoc

Attachments with Announcement:

issuer: Semperit AG Holding
Modecenterstrasse 22
A-1030 Wien
phone: +43 1 79 777-310
FAX: +43 1 79 777-602
mail: judit.helenyi@semperitgroup.com
WWW: www.semperitgroup.com
ISIN: AT0000785555
stockmarkets: Wien
language: English

Digital press kit: http://www.ots.at/pressemappe/2918/aom

Rückfragen & Kontakt:

Monika Riedel
Director Group Brand Management, Corporate Spokesperson
+43 676 8715 8620

Judit Helenyi
Director Investor Relations
+43 676 8715 8310